- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940270
Ultrasound Screening of the Aorta in Giant Cell Arteritis (GCA-PANIC)
GCA Panic - Giant Cell Arteritis: Predicting Aneurysms in Clinics
The goal of this observational study is to find out whether ultrasound can reliably detect dilatation and aneurysms of the aorta, the main blood vessel that carries blood from the heart to the rest of the body, in people with giant cell arteritis (GCA). GCA causes inflammation in the blood vessel walls. It can affect the aorta and increase the risk of aortic dilatation and aneurysms. Aortic dilatation is an abnormal widening of the aorta. When it becomes large, it is called an aneurysm, and can lead to serious complications.
The main questions the study aims to answer are:
How accurately can ultrasound performed by rheumatologists detect dilatation and aneurysms of the aorta compared with computed tomography (CT) angiography, which provides detailed images of the aorta?
How consistently do different rheumatologists evaluate the aorta using ultrasound?
How often is aortic dilatation and aneurysms found in people with GCA who previously had signs of inflammation in the aorta on a PET-CT scan?
Researchers will compare ultrasound measurements with CT angiography findings to assess how well ultrasound detects aortic dilatation and aneurysms.
The study will include 102 participants: 82 people with GCA and previous signs of aortic inflammation on PET-CT, 10 people with GCA and a known aortic dilatation or aneurysm, and 10 people with aortic dilatation or aneurysm not caused by inflammation.
Participants will undergo an ultrasound examination of the ascending aorta, the part of the aorta closest to the heart. Participants will also undergo CT angiography of the aorta, which uses X-rays and contrast dye to produce detailed images of the blood vessel. The ultrasound measurements will be compared with the CT angiography findings. The ultrasound evaluations of the ultrasound performing rheumatologists will be compared with evaluations of a blinded assessor.
The long-term aim is to determine whether ultrasound could be a useful, non-invasive screening method to help identify aortic dilatation and aneurysms in people with GCA.
Aperçu de l'étude
Statut
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Stavros Chrysidis, MD PhD
- Numéro de téléphone: 0045 79 40 67 41
- E-mail: stavros.chrysidis@rsyd.dk
Sauvegarde des contacts de l'étude
- Nom: Nikoletta Svendsen, MD MSc
- Numéro de téléphone: 0045 73 65 40 30
- E-mail: nikoletta.svendsen@rsyd.dk
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
GCA patients will be recruited from the five Rheumatology clinics of the Region of Southern Denmark (Odense University Hospital, Svendborg Hospital, Esbjerg Hospital, the Danish Hospital for Rheumatic Diseases, Lillebælt Hospital). Non-GCA patients will be recruited from the Cardiology clinic of Esbjerg Hospital.
La description
Inclusion Criteria:
- GCA diagnosis with initial PET-CT involvement of thoracic aorta for the "GCA without known dilatation or aneurysm of the aorta" cohort
- Established ascending aortic dilatation or anerysm through CT or MR angiography of the aorta and a history of GCA for the "GCA with known dilatation or aneurysm of the aorta" cohort
- Established ascending aortic dilatation or aneurysm through CT or MR angiography of the aorta and no history of vasculitis for the "Non-GCA with known dilatation or aneurysm of the aorta" cohort
Exclusion Criteria:
- Inability to consent
- Inability to undergo ultrasound of the aorta
- BMI ≥ 40
- Previous operation for aortic structural damage
Specifically for the "GCA without known dilatation or aneurysm of the aorta" cohort:
- Inability to undergo CT angiography of the aorta
- Unknown kidney function and unwillingness to have it tested before CT angiography
- Known kidney failure (eGFR<30ml/min/1.73m3)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
GCA without known aortic dilatation or aneurysm but known aortic inflammation in PET-CT at debut
GCA patients with involvement of the thoracic aorta in the initial PET-CT upon diagnosis who have or have had regular follow-ups in the Rheumatology Clinics of the Region of Southern Denmark, who do not have known aortic dilatation or aneurysm, will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta and CT angiography of the aorta. Inclusion will stop at 82 subjects. |
|
GCA with known aortic dilatation or aneurysm
GCA patients with CT or MR angiography-established dilatation or aneurysm of the thoracic aorta who have or have had regular follow-ups in the Rheumatology clinics of the Region of Southern Denmark will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects |
|
Non-GCA with known aortic dilatation or aneurysm
Patients with CT or MR angiography established dilatation or aneurysm of the thoracic aorta on a non-inflammatory basis who have regular follow-ups in the Cardiology Clinic in Esbjerg Hospital will be invited to the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnostic accuracy of thoracic aorta ultrasound for detecting aortic dilatation and aneurysms
Délai: At the baseline study visit.
|
The ability of ultrasound measurements of the thoracic aorta to identify aortic dilatation or aneurysms will be evaluated using CT angiography as the reference standard. A receiver operating characteristic (ROC) curve will be used to assess how well the ultrasound measurements distinguish between participants with and without aortic dilatation or aneurysms. Diagnostic performance will be summarized by calculating the area under the ROC curve (AUC). |
At the baseline study visit.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Agreement between assessors in ultrasound measurements of the thoracic aorta
Délai: At the baseline study visit.
|
Agreement between rheumatologists performing ultrasound examinations and an independent, blinded assessor will be evaluated by comparing their measurements of the thoracic aorta. Agreement will be quantified using the intraclass correlation coefficient (ICC), which indicates how closely the measurements agree. A two-way random-effects model assessing absolute agreement will be used (ICC[2,1]). |
At the baseline study visit.
|
|
Prevalence of thoracic aortic dilatation and aneurysm in GCA patients with prior FDG-PET/CT-confirmed aortic uptake
Délai: At the baseline study visit.
|
The prevalence of thoracic aortic dilatation and aneurysm will be assessed among the patients with giant cell arteritis (GCA) and aortic FDG uptake on PET/CT at diagnosis. Thoracic aortic diameters will be measured with CT angiography and aortic dilatation and aneurysm will be classified according to prespecified diameter-based diagnostic criteria. Prevalence will be calculated as the number of participants meeting the criteria for aortic dilatation or aneurysm at the study assessment divided by the total number of this cohort's participants with evaluable CT angiography scans. Aortic dilatation and aneurysm will also be reported separately, where applicable. |
At the baseline study visit.
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Stavros Chrysidis, MD PhD, University of Southern Denmark
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies auto-immunes du système nerveux
- Maladies de la peau
- Maladies de la peau, vasculaire
- Maladies aortiques
- Vascularite
- Anévrisme
- Vascularite, système nerveux central
- Artérite
- Maladies de la peau et du tissu conjonctif
- Anévrisme aortique
- Artérite à cellules géantes
Autres numéros d'identification d'étude
- 115537
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .